Back to Authors

Boison, Detlev

0000-0002-7740-5781

Mayo Clinic

Rutgers, The State University of New Jersey

Citations 1

Adenosine A 2A receptor blockade prevents cisplatin-induced impairments in neurogenesis and cognitive function
Oliveros, Alfredo , Yoo, Ki Hyun , Rashid, Mohammad Abdur , Corujo-Ramirez, Ana , Hur, Benjamin, Sung, Jaeyun , Liu, Yuanhang , Hawse, John R. , Jang, Mi‐Hyeon , Sung, Jaeyun , Choi, Doo‐Sup , Boison, Detlev

Proceedings of the National Academy of Sciences | July 7, 2022 | Volume: 119 | Issue: 28 | Pages: No page available

10.1073/pnas.2206415119 Get It

Chemotherapy-induced cognitive impairment (CICI) has emerged as a significant medical problem without therapeutic options. Using the platinum-based chemotherapy cisplatin to model CICI, we revealed robust elevations in the adenosine A 2A receptor (A 2A R) and its downstream effectors, cAMP and CREB, by cisplatin in the adult mouse hippocampus, a critical brain structure for learning and memory. Notably, A 2A R inhibition by the Food and Drug Administration–approved A 2A R antagonist KW-6002 prevented cisplatin-induced impairments in neural progenitor proliferation and dendrite morphogenesis of adult-born neurons, while improving memory and anxiety-like behavior, without affecting tumor growth or cisplatin’s antitumor activity. Collectively, our study identifies A 2A R signaling as a key pathway that can be therapeutically targeted to prevent cisplatin-induced cognitive impairments.